OTC : HOOK

HOOKIPA Pharma Inc.

$1.15 USD

$0 (0.0%)

Volume
0
Average Volume
11.96K
Market Capitalization
$14.4M
P/E Ratio
-0.71
Dividend Yield
0.00%
Price Target
$3.00
Year High
$1.55
Year Low
$0.81
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$3.93
Company Overview

OTC

Malte Peters

Biotechnology

Healthcare

HOOK

82

US

USD

https://www.hookipapharma.com

431 890 6360

43906K209

0001760542

Liquidity Metrics

0.02

3.93

3.93

2.60

0.00

Sales & Valuation

$9.7M

1.64

0.51

-2.03

-0.56

Profitability

-$1.09

-$13.84M

-195.62%

-195.62%

-54.85%

-32.66%

P/E Metrics

-0.71

0.01

0.01

Analyst Price Target & Rating

$3.00

$3.00

$3.00

N/A

0/5

9 Analysts

-61.67%

Financial Health Scores

-13.42

2/9

$38.52M

$52.71M

$24.02M

-$56.11M

Key Metrics (TTM)

-$19.29M

-2.19

1.18

3.93

-54.85%

-61.30%

-118.02%

-49.33%

-6736 days

Company Executives
Name Title
Malte Peters Chief Executive Officer, President & Director
Daniel D. Pinschewer Co-Founder & Member of Scientific Advisory Board
Mark Winderlich Chief Research & Development Officer
Mary Theresa Coelho Executive Vice President, Chief Financial Officer & Director
Poll Results

No votes yet today — be the first to share your view!

About HOOKIPA Pharma Inc. (OTC:HOOK) Stock

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company’s immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers with enrollment completed in a Phase 1/2 clinical trial; and HB-300, which targets self-antigens for the treatment of prostate cancer. It is also developing HB-400 for the treatment of Hepatitis B that is in Phase I of clinical trial; ... and HB-500 for the treatment of Human Immunodeficiency Virus (HIV) that is in Phase I of clinical trial. The company has a collaboration and license agreement with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis, or prevention of the hepatitis B virus (HBV) and the HIV. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.

Frequently Asked Questions

What is the current HOOKIPA Pharma Inc. (HOOK) stock price?

HOOKIPA Pharma Inc.(OTC:HOOK) stock price is $1.15 in the last trading session. During the trading session, HOOK stock reached the peak price of $1.55 while $0.811 was the lowest point it dropped to. The percentage change in HOOK stock occurred in the recent session was 0.0% while the dollar amount for the price change in HOOK stock was $0.

HOOK's industry and sector of operation?

The OTC listed HOOK is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of HOOK?

Malte Peters | Chief Executive Officer, President & Director
Daniel D. Pinschewer | Co-Founder & Member of Scientific Advisory Board
Mark Winderlich | Chief Research & Development Officer
Mary Theresa Coelho | Executive Vice President, Chief Financial Officer & Director
|

How many employees does HOOK have?

Number of HOOK employees currently stands at 82. HOOK operates from 350 Fifth Avenue, New York, NY 10118, US.

Link for HOOK official website?

Official Website of HOOK is: https://www.hookipapharma.com

How do I contact HOOK?

HOOK could be contacted at phone #431 890 6360 and can also be accessed through its website. HOOK operates from 350 Fifth Avenue, New York, NY 10118, US.

How many shares of HOOK are traded daily?

The average number of HOOK shares traded daily for last 3 months was 11.96K.

What is the market cap of HOOK currently?

The market value of HOOK currently stands at $14.4M with its latest stock price at $1.15